Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 21, 2009

Athera Signs On Richter-Helm to Produce Cardiovascular Protein Therapeutic

  • Richter-Helm BioLogics will help Athera Biotechnologies with development and manufacturing of its cardiovascular product. The recombinant protein Annexin A5 is intended for the treatment of patients with acute coronary syndrome who are at risk for myocardial infarction.

    “We have now secured cost-competitive and high-quality production for clinical and commercial use,” notes Carina Schmidt, CEO of Athera Biotechnologies.

    Athera’s candidate reported works by preventing plaque rupture and athero-thrombosis through binding of the protein, Annexin A5, to endothelium. It was produced using Richter-Helm's E. coli-based expression system.

    This agreement could include future large-volume commercial production of the molecule for Athera. Richter-Helm will initiate strain and process development of the new process, reaching a 1000 L production scale.

    ---

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »